Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression
Creators
- 1. Department of Microbiology, College of Medicine, University of Sulaimani, Sulaimaniyah, Kurdistan Region-Iraq (Iraq)
- 2. Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Huddinge (Sweden)
- 3. Department of Biology, College of Science, Salahaddin University-Erbil, 44002, Erbil, Kurdistan Region-Iraq (Iraq)
- 4. Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, 45122, Essen (Germany)
- 5. Department of Clinical Genetics, Centre for Rare Diseases, Karolinska University Hospital, SE-171 76, Stockholm (Sweden)
- 6. Department of Biochemistry, College of Medicine, University of Sulaimani, Sulaimaniyah, Kurdistan Region-Iraq (Iraq)
Description
Highlights: • The downstream targets of ITK-FER and ITK-SYK were explored and STAT3 is highly phosphorylated by these fusion kinases. • The CD69 T-cell activation marker was significantly elevated. • Upon expression of FER, ITK-FER, SYK, and ITK-SYK, the auto-phosphorylation events in HEK 293T cells were induced, even under serum starvations. Many cancer types carry mutations in protein tyrosine kinase (PTK) and such alterations frequently drive tumor progression. One category is gene translocation of PTKs yielding chimeric proteins with transforming capacity. In this study, we characterized the role of ITK-FER [Interleukin-2-inducible T-cell Kinase (ITK) gene fused with Feline Encephalitis Virus-Related kinase (FER) gene] and ITK-SYK [Interleukin-2-inducible T-cell Kinase (ITK) gene fused with the Spleen Tyrosine Kinase (SYK)] in Peripheral T Cell Lymphoma (PTCL) signaling. We observed an induction of tyrosine phosphorylation events in the presence of both ITK-FER and ITK-SYK. The downstream targets of ITK-FER and ITK-SYK were explored and STAT3 was found to be highly phosphorylated by these fusion kinases. In addition, the CD69 T-cell activation marker was significantly elevated. Apart from tyrosine kinase inhibitors acting directly on the fusions, we believe that drugs acting on downstream targets could serve as alternative cancer therapies for fusion PTKs.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2018.09.019Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2018.09.019;
- PII
- S0006291X18319351;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 504
- Journal Issue
- 4
- Journal Page Range
- p. 749-752
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 53024356
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- DRUGS; ENCEPHALITIS; LYMPHOKINES; LYMPHOMAS; ONCOGENES; PHOSPHOTRANSFERASES; SPLEEN; TYROSINE; VIRUSES
- Descriptors DEC
- AMINO ACIDS; BODY; CARBOXYLIC ACIDS; DISEASES; ENZYMES; GENES; GROWTH FACTORS; HYDROXY ACIDS; IMMUNE SYSTEM DISEASES; MICROORGANISMS; MITOGENS; NEOPLASMS; NERVOUS SYSTEM DISEASES; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANS; PARASITES; PHOSPHORUS-GROUP TRANSFERASES; PROTEINS; TRANSFERASES
Optional Information
- Copyright
- Copyright (c) 2018 Elsevier Inc. All rights reserved.